Evaluation of reticulated gelatin-hibiscus-propolis against intestinal commensal species commonly associated with urinary tract infections

Future Microbiology

Volumn 12, Issue 6, 2017, Pages 505-513

  Olier, Maïwenn ^a   Sekkal, Soraya ^a   Harkat, Cherryl ^a   Eutamene, Hélène ^a   Theodorou, Vassilia ^a  

^a TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

Author keywords

commensal Escherichia coli; Enterococcus; fecal colonization; fecal opportunistic uropathogens; reticulated gelatin; urinary tract infections

Indexed keywords

ANTIBIOTIC AGENT; GELATIN; HIBISCUS SABDARIFFA EXTRACT; NATURAL PRODUCT; PROPOLIS; RETICULATED GELATIN HIBISCUS AND PROPOLIS; STREPTOMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; COMMENSAL; COMMENSAL ESCHERICHIA COLI; CONTROLLED STUDY; DRUG EFFICACY; ENTEROCOCCUS; FECES MICROFLORA; FEMALE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANIMAL; APITHERAPY; BACTERIUM ADHERENCE; DRUG EFFECTS; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FECES; HIBISCUS; INTESTINE; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; SYMBIOSIS; UROPATHOGENIC ESCHERICHIA COLI; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; APITHERAPY; BACTERIAL ADHESION; ENTEROBACTERIACEAE; ENTEROCOCCUS; ESCHERICHIA COLI; FECES; FEMALE; GELATIN; HIBISCUS; INTESTINES; PHYTOTHERAPY; PROPOLIS; RATS, WISTAR; STREPTOMYCIN; SYMBIOSIS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 85019588272     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0175     Document Type: Article

References (26)

1. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J. Urol. 173, 1281-1287 (2005).
2. Johansen TEB, Cek M, Naber KG, Stratchounski L, Svendsen MV, Tenke P. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int. J. Antimicrob. Agents 28(Suppl. 1), S91-S107 (2006).
3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269-284 (2015).
4. Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J. Infect. Dis. 172, 440-445 (1995).
5. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J. Urol. 157, 1127-1129 (1997).
6. Xie J, Foxman B, Zhang L, Marrs CF. Molecular epidemiologic identification of Escherichia coli genes that are potentially involved in movement of the organism from the intestinal tract to the vagina and bladder. J. Clin. Microbiol. 44, 2434-2441 (2006).
7. Moreno E, Andreu A, Pigrau C, Kuskowski MA, Johnson JR, Prats G. Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host. J. Clin. Microbiol. 46, 2529-2534 (2008).
8. Herzer PJ, Inouye S, Inouye M, Whittam TS. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. J. Bacteriol. 172, 6175-6181 (1990).
9. Escobar-Paramo P, Grenet K, Le Menac'h A et al. Large-scale population structure of human commensal Escherichia coli isolates. Appl. Environ. Microbiol. 70, 5698-5700 (2004).
10. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 8, 207-217 (2010).
11. Picard B, Garcia JS, Gouriou S et al. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect. Immun. 67, 546-553 (1999).
12. Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J. Clin. Microbiol. 40, 3951-3955 (2002).
13. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J. Infect. Dis. 181, 261-272 (2000).
14. Fisher K, Phillips C. The ecology, epidemiology and virulence of Enterococcus. Microbiology 155, 1749-1757 (2009).
15. García-Larrosa A, Alexe O. Efficacy and safety of a medical device versus placebo in the early treatment of patients with symptoms of urinary tract infection: a randomized controlled trial. Clin. Microbiol. 5, 233 (2016).
16. Esteban Carretero J, Durbán Reguera F, López-Argüeta Alvarez S, López Montes J. A comparative analysis of response to ORS (oral rehydration solution) vs ORS +RP in pediatric patients with acute diarrhea. Rev. Esp. Enferm. Dig. 101, 41-48 (2009).
17. Allegrini A, Costantini MA. RP for the treatment of acute diarrhoea in adults. J. Gastointest. Dig. Syst. 2, 110-115 (2012).
18. Frasca G, Cardile V, Puglia C, Bonina C, Bonina F. RP reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin. Exp. Gastroenterol. 5, 61-67 (2012).
19. Scaldaferri F, Lopetuso LR, Petito V et al. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: emerging role for 'gut barrier protectors' in IBD? United European Gastroenterol. J. 2, 113-122 (2014).
20. de Servi B, Moreira da Silva R, Meloni M et al. New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity. Presented at (oral communication): The 33rd Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques, Nantes, France, 30 March 2012.
21. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr. Opin. Infect. Dis. 23, 320-326 (2010).
22. Pitout JD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J. Clin. Microbiol. 43, 2844-2849 (2005).
23. Myhal ML, Laux DC, Cohen PS. Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice. Eur. J. Clin. Microbiol. 1, 186-192 (1982).
24. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals 8th edition. doi:10.17226/12910 National Academies Press, Washington DC (2011).
25. Alteri CJ, Mobley HLT. Metabolism and fitness of urinary tract pathogens. Microbiol. Spectr. 3(3), doi:10.1128/microbiolspec. MBP-0016-2015 (2015).
26. Li H, Limenitakis JP, Fuhrer T et al. The outer mucus layer hosts a distinct intestinal microbial niche. Nat. Commun. 6, 8292 (2015).